CANbridge to Present CAN106 Phase 1 Data at the European Hematology Association 2022 Congress

Major Breakthrough | China’s National Medical Products Administration potentially to grant new rare disease drugs market exclusivity for up to seven years

CANbridge Pharmaceuticals Appoints Pauline Li as Senior Vice President of Clinical Development and Operations

CANbridge-UMass Chan Medical School Gene Therapy Research to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

First Study from the CANbridge UMass Chan Medical School Rare Disease Gene Therapy Research Collaboration 

CANbridge Pharmaceuticals CAN108 New Drug Application/Orphan Drug Registration (NDA/ORD) for Alagille Syndrome Accepted by the Taiwan Food and Drug Administration

First Patient Dosed in CAN106 Phase 1b/2 Trial for Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in China

CANbridge Announces Financial Results and Corporate Updates for the Twelve Months Ended December 31, 2021

CANbridge Announces Approval of CAN108for Rare Liver Disease, Alagille Syndrome, Under the Early and Pilot Implementation Policy in Boao Lecheng International Medical Tourism Pilot Zone

CANbridge Pharmaceuticals Appoints

Dr. Lan Hu as New Independent Director